ProCE Banner Activity

SWOG 1512: Phase II Study of Neoadjuvant Pembrolizumab in Patients With Resectable Desmoplastic Melanoma

Slideset Download
Conference Coverage
In patients with locally advanced desmoplastic melanoma, neoadjuvant pembrolizumab was associated with a pathologic CR rate of 55% and led to no toxicity-related surgery cancellations.

Released: June 10, 2022

Expiration: June 09, 2023

No longer available for credit.


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from



Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.


Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab